Abstracts tagged "Biologicals"

Abstract Number: 1154 • ACR Convergence 2021
What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
Sabina Gall, Uta Kiltz, Tanja Kobylinski, Ioana Andreica, Kristina Vaupel, Xenofon Baraliakos and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The market share of biosimilars (bsDMARDs) is steadily growing, not only in rheumatologic care. Although data on efficacy, efficiency and safety have been generated…
Abstract Number: 1333 • ACR Convergence 2021
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Peter Nash¹, Lai-Shan Tam², Wen-Chan Tsai³, Ying-Ying Leung⁴, Daniel Furtner⁵, Shihong Sheng⁶, Yanli Wang⁶, May Shawi⁷, Alexa Kollmeier⁸, Jonathan Sherlock⁹ and Daniel Cua⁶, ¹Griffith University, Brisbane, Australia, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Janssen Research & Development, LLC, Kaohsiung City, Taiwan (Republic of China), ⁴Singapore General Hospital and Duke-NUS Medical School, Singapore, Singapore, ⁵Janssen, a division of Johnson & Johnson Pte. Ltd., Singapore, Singapore, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Oxford, Spring House, PA
Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts)…
Abstract Number: 1443 • ACR Convergence 2021
Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis
Nathan den Broeder¹, Lise Verhoef², Yael De Man³, Marc Kok⁴, Rogier Thurlings⁵, Wilfred van der Weele⁶, Bart van den Bemt⁷, Frank van den Hoogen⁸, Aatke van der Maas⁹ and Alfons den Broeder¹⁰, ¹Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Ziekenhuisgroep Twente (Hospital Group Twente), Borne, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Reade, Amsterdam, Netherlands, ⁷Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁸Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁹St Maartenskliniek, Nijmegen, Gelderland, Netherlands, ¹⁰Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: The optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 6…
Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
Abstract Number: 1833 • ACR Convergence 2021
Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Muhammad Ajmal¹, Jawad Bilal¹, Syed Arsalan Ahmed Naqvi², Irbaz Bin Riaz³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani¹, Yi-Shao Liu⁵, Sandipan Bhattacharjee⁵, Roxanne Bogucka⁵, Noureen Asghar⁶ and Kent Kwoh¹, ¹University of Arizona, Tucson, AZ, ²Dow University of Health Sciences, Karachi, Pakistan, ³Mayo Clinic, Phoenix, AZ, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Texas at Austin, Austin, TX, ⁶Dow University of Health Sciences, Karachi
Background/Purpose: The efficacy of biologics and targeted synthetic disease modifying antirheumatic agents approved for treatment of psoriatic arthritis (PsA) is well documented, but cardiovascular safety…
Abstract Number: 0097 • ACR Convergence 2021
Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Anne Regierer⁵, Jutta Richter⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Janus kinase inhibitors (JAK-i) offer a potent mode of action to treat rheumatic diseases. Little is known on the course and outcome of SARS-CoV-2…
Abstract Number: 0671 • ACR Convergence 2021
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
Aaron Broadwell¹, John Albert², Brian LaMoreaux³ and Lissa Padnick-Silver³, ¹Rheumatology and Osteoporosis Specialists, Shreveport, LA, ²Rheumatic Disease Center, Milwaukee, WI, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…
Abstract Number: 1156 • ACR Convergence 2021
Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry
Jessica Walsh¹, Kelley Myers², Carol Mansfield², William Tillett³, Peter Nash⁴, Colton Leach², William Nowell⁵, Kelly Gavigan⁵, Patrick Zueger⁶, Erin McDearmon-Blondell⁷ and Alexis Ogdie-Beatty⁸, ¹Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ²RTI Health Solutions, Research Triangle Park, NC, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Griffith University, Brisbane, Australia, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶AbbVie Inc., Mettawa, IL, ⁷AbbVie Inc., Elmhurst, IL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: To optimize patient-provider shared decision-making, it is important to understand patients’ experience with psoriatic arthritis (PsA) and its treatment, including how treatment experience may…
Abstract Number: 1337 • ACR Convergence 2021
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Stefan Siebert¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Elke Theander¹⁰, Laure Gossec¹¹ and Josef Smolen¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰Janssen Cilag, Lund, Sweden, ¹¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriasis and PsA are associated with multiple comorbidities such as cardiovascular disease and metabolic syndrome. These comorbidities may render patients prone to developing adverse…
Abstract Number: 1459 • ACR Convergence 2021
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
Eric Morand¹, Gabriel Abreu², Richard Furie³ and Raj Tummala⁴, ¹Monash University, Melbourne, Australia, ²BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a treat-to-target (T2T) endpoint for SLE, is prospectively validated as protective from flares and damage accrual.1 LLDAS…
Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Kenneth Kalunian³, Konstantina Psachoulia⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁴, ¹Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ²Monash University, Melbourne, Australia, ³University of California, La Jolla, CA, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…
Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Marijn Vis¹, Pascal Richette², Ramirez Julio³, Marlies Neuhold⁴, Robert Wapenaar⁵, Elke Theander⁶, Wim Noel⁷, May Shawi⁸, Alexa Kollmeier⁹ and William Tillett¹⁰, ¹Erasmus MC, Badhoevedorp, Netherlands, ²Lariboisiere Hospital, Paris, France, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Janssen-Cilag, Zug, Switzerland, ⁵Janssen-Cilag BV, Breda, Netherlands, ⁶Janssen Cilag, Lund, Sweden, ⁷Janssen Pharmaceutica, Vilvoorde, Belgium, ⁸Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
Abstract Number: 0103 • ACR Convergence 2021
Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
Laura Boekel¹, Femke Hooijberg¹, Erik Vogelzang², Maureen Leeuw¹, Sadaf Atiqi¹, Ronald van Vollenhoven³, Alexandre Voskuyl², Irene van der Horst-Bruinsma², Willem Lems¹, Taco Kuijpers², Marieke van Ham⁴, Luuk Wieske², Filip Eftimov², Maurice Steenhuis⁴, Sofie Keijzer⁴, Olvi Christianawati⁴, Floris Loeff⁴, Sander Tas⁵, Mike Nurmohamed⁶, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Retrospective studies have suggested that patients with rheumatic diseases may be at increased risk of severe COVID-19 related disease, and that this risk may…
Abstract Number: 0753 • ACR Convergence 2021
Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
John Davelaar¹, Naomi Jessurun², Sander Tas³, Mike Nurmohamed⁴, Bart van den Bemt⁵ and Harald Vonkeman⁶, ¹Netherlands Pharmacovigilance Centre Lareb, Utrecht, Netherlands, ²Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁴Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁶Medisch Spectrum Twente; University of Twente, Enschede, Netherlands
Background/Purpose: Health care professionals tend to focus on adverse drug reactions (ADRs) with the highest clinical impact. Subsequently, ADRs with less obvious clinical impact but…
Abstract Number: 1157 • ACR Convergence 2021
Patient Perspective on the Non Medical Switch of Originator to Its Biosimilar in Inflammatory Arthritis Using a Social Media Survey
David Vega Morales¹, Alejandro Garza-Alpirez² and Carlos Andrés Díaz-Garza², ¹Hospital Universitario, Garcia, Mexico, ²Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, San Pedro, Mexico
Background/Purpose: The use of biosimilars instead of its originator is a controversial subject with many implications. It is considered that a non medical switch should…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].